Tag: Alirocumab

In January 2017, a U.S. judge ordered Praluent off the market within 30 days, citing patent infringement, a decision that created significant uncertainty for patients and healthcare providers. However, this ban never took permanent effect in the United States, raising questions about the drug's true market status and **why was Praluent pulled from the market** in some regions more recently. The situation involves complex legal battles, evolving market strategies, and global supply chain challenges.

PCSK9 inhibitors can significantly lower "bad" low-density lipoprotein (LDL) cholesterol by 50% to 70%, offering a powerful treatment option for patients who cannot achieve their target levels with statins alone. These advanced medications target a specific protein in the liver to increase cholesterol clearance from the bloodstream. This guide explores the different drugs that are PCSK9 inhibitors, their mechanisms, and their role in modern cardiovascular care.